DiaMedica: The 200th Patient Is In — Now the Calendar Is the Risk
ReMEDy2 has cleared its interim-analysis enrollment hurdle, but the FGR readout, the rat tox report and the Canadian Phase 2 all slipped right in a single quarter
DMAC · Earnings Call · 2026-11-13
Two switches flipped, one clock started
DiaMedica is a ~$500 million-market-cap clinical-stage biotech with one molecule, DM199 (rinbifetapenem alfa), a recombinant KLK1, and three shots on goal: preeclampsia, fetal growth restriction and acute ischemic stroke. On this call, two of the three programs crossed thresholds that had been described for quarters as "coming."
Enrollment in the first two cohorts of the investigator-sponsored fetal growth restriction study is complete — 12 women, 6 at 5 µg/kg and 6 at 10 µg/kg, run out of Tygerberg Hospital in Cape Town. And more consequentially, ReMEDy2 hit the number that matters: “in October, we enrolled the 200th participant in ReMEDy2, our pivotal phase 2/3 trial in acute ischemic stroke. With this, we attained the prespecified enrollment threshold required for the REMEDY 2 interim analysis.” — Dietrich John Pauls, Chief Executive Officer · 2026-11-13
That is a genuinely new keyword for this company: enrollment threshold does not appear in prior quarters' vocabulary, where the stroke conversation was all about enrollment rate, site activation and slipping timelines. After 90 days of follow-up on patient 200 plus data prep, the independent DSMB reads the modified Rankin 0–1 endpoint. Management's guide: Q1 2027.
The other fresh vocabulary is diagnostic of what investors will actually see on November 24: birth weight centile, 3rd percentile severity stratification, and pharmacologic activity measured through umbilical artery Doppler indices. Rick Pauls framed the bar plainly: “these patients typically only worsen. So what we believe is that even a stabilization would be good, whereas we could. If we can see an absolute reduction, that would be great.” — Dietrich John Pauls, Chief Executive Officer · 2026-11-13
What quietly moved right
Here is the tension in this report. Three deliverables that were dated in prior calls are now dated later, and none of them was framed as a delay.
First, the KOL event. On the August call the CEO closed with: “please keep an eye out for a press release announcing the date of our KOL event focusing on early onset fetal growth restriction.” — Dietrich Pauls, Chief Executive Officer · 2026-08-11 Analysts on that call were told to expect Cohort 1 data in September. It is now November 24 — and it is a two-cohort readout of 12 patients, not six. Better dataset, later date.
Second, the rat toxicology study. In August, on the same call, management said of the study supporting the US preeclampsia IND: “we should be completing that in the early part of September. The plan would be the idea then to submit for a U.S. IND.” — Dietrich Pauls, Chief Executive Officer · 2026-08-11 This quarter the language is “we expect the pharmacokinetics and pharmacologic results in the coming weeks.” — Dietrich John Pauls, Chief Executive Officer · 2026-11-13 The in-life portion is done and well tolerated — but the FDA-facing package, the item management called "the last piece," has been in a holding pattern for two months.
Third, the company-sponsored Phase 2 in early onset preeclampsia. Guidance has been consistent for three calls — Canada and the UK, roughly 30 patients, three dose levels. The date has not been. In May: “for the company-sponsored trial for the early onset preeclampsia, we're targeting late this year.” — Dietrich Pauls, Chief Executive Officer · 2026-08-11 In November: “we would still like to see enrollment this year, but worst case it should be early in 2027.” — Dietrich John Pauls, Chief Executive Officer · 2026-11-13 Same for the addressing FDA feedback track — the tone is procedural confidence, the calendar is elastic.
The setup that matters is the resample, not the readout date
The stroke interim is the whole equity story, and the decision tree has been unchanged for at least four quarters — which is itself informative. Chase Knickerbocker has asked essentially the same question in March, May, August and again Thursday: what happens at the interim? The answer today is the same skeleton, now with an operational twist: “if we are not seeing a drug effect, we will stop the study for futility. Otherwise, if we see a drug effect, a lot of it depends on the statistical analysis plan, but if we see that it is a drug effect that is comparable to what we saw in our phase 2, we would be looking at closer to 300 patients. If we see a drug effect closer to, you know, 6 percent, we would be looking at the high end of 728.” — Dietrich John Pauls, Chief Executive Officer · 2026-11-13 Pauls also gave the practical tell for January: they expect to be near 300 randomized by the time the DSMB convenes, meaning the resample size is less a fundraising mandate than a signal about effect magnitude. The drug effect question is no longer theoretical — but it is still entirely binary.
The trial design itself is worth restating because it explains why this is a small-cap and not a mid-cap: ReMEDy2 enrolls patients ineligible for mechanical thrombectomy, the population where reperfusion options run out and where a collateral-flow drug has room to show something.
The balance sheet gives them one more swing
Scott Kellen's numbers are the constraint on everything above. Cash and short-term investments fell to $34.9M from $59.9M at year-end 2025; nine-month operating burn was $26.0M against $21.3M a year earlier; Q3 net loss was $11.3M, or $0.21 a share, versus $8.6M a year ago. Runway is guided into Q4 2027 — which comfortably covers the Q1 2027 DSMB read, but not a 728-patient expansion plus a Phase 2 preeclampsia program plus an IND-enabling package without another raise.
Research and development expense has compounded from roughly $1M a quarter in 2018 to $9.2M this quarter — a 40% year-over-year increase that management attributed to clinical team expansion, ReMEDy2's global footprint, Phase 2 preeclampsia start-up and additional reproductive toxicology. The cash runway sits at about 5.4 quarters, well below the 16-quarter cushion of 2021Q4, and the net loss is running at a record rate. With the stock 18% below its November 4 high of $10.77 and up 14.6% over 90 days, the equity has already de-rated into the print.
The honest scorecard
What changed: the stroke trial is now past its enrollment gate, and the fetal growth dataset doubled from what was promised. What did not change: every date management offers is a soft one, the resample logic is identical to four quarters ago, and no theme here is being ridden — early onset FGR and preeclampsia are company-unique science, not a market wave, and they show up nowhere in the broader keyword universe. That is the bullish case and the bearish case at once: nobody else is doing this, and nobody else is paying for it.
Analysts clearly wanted the November 24 data early — Thomas Flaten probed birth-weight benchmarking, Stacy Ku probed concomitant preeclampsia and Doppler cadence. Pauls's answer was the same both times: “if you could hang tight here, we will have that here, in a week and a half.” — Dietrich John Pauls, Chief Executive Officer · 2026-11-13 Ten days from now, this dossier's central uncertainty becomes a number.